Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
International Journal of Radiation Oncology, Biology, Physics|December 3, 2002
ZD6126: a novel small molecule vascular targeting agentDavid C Blakey, Susan E Ashton, F Russell Westwood, et al.Journal of the National Cancer Institute|November 15, 2007
Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in ratsSarah Gould, F Russell Westwood, Jon O Curwen, et al.Neoplasia (New York, N.Y.)|May 31, 2007
Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic ratsDaniel P Bradley, Jean J Tessier, Susan E Ashton, et al.Cancer Research|October 18, 2002
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapyAlan E Wakeling, Simon P Guy, Jim R Woodburn, et al.Microvascular Research|March 15, 2006
Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126Elizabeth R Cullis, Tammy L Kalber, Susan E Ashton, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2010
Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancersNeil R Smith, Dawn Baker, Neil H James, et al.Journal of Medicinal Chemistry|January 22, 2005
Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugsPhilip Reigan, Philip N Edwards, Abdul Gbaj, et al.Cancer Discovery|June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerDarren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.Pageof 1